ProShare Advisors
GYRE icon

ProShare Advisors’s Gyre Therapeutics GYRE Stock Holding History

ProShare Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-36
Closed -$134K – 2516
2014
Q1 		$134K Buy
+36
New +$133K ﹤0.01% 2634
2013
Q4 		– Sell
-38
Closed -$157K – 1560
2013
Q3 		$157K Buy
38
+8
+27% +$32.2K ﹤0.01% 2282
2013
Q2 		$102K Buy
+30
New +$114K ﹤0.01% 2247

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ProShare Advisors's GYRE Position: Q2 2014 in Review

ProShare Advisors sold out of Gyre Therapeutics (GYRE) in Q2 2014, closing a stake of 36 shares — an estimated $134K sold.

ProShare Advisors first reported a position in GYRE in Q2 2013 and held it in 3 quarters. The position peaked at $157K in Q3 2013. 63 funds tracked by Wall St. Rank hold GYRE as of Q2 2014.

  • ProShare Advisors reported no remaining Gyre Therapeutics position as of Q2 2014 after selling out during the quarter.
  • ProShare Advisors sold 36 Gyre Therapeutics shares in Q2 2014, an estimated $134K.
  • ProShare Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 3 quarters.
  • ProShare Advisors's Gyre Therapeutics position peaked at $157K in Q3 2013.
  • 63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2014.

Based on ProShare Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.